批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
>>>原始批准或临时批准<<<
| 审批日期 | 提交号 | 审批结论 | 提交分类 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2012/12/20 |
ORIG-1(原始申请) |
Approval |
Type 5 - New Formulation or New Manufacturer |
STANDARD
|
|
|
>>>补充申请<<<
| 审批日期 | 提交号 | 审批结论 | 补充类别或审批类型 | 审评优先级;罕用药状态 | 通知信、审评文件、说明书、包装标签 | 备注 |
| 2019/06/24 |
SUPPL-11(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2017/09/20 |
SUPPL-10(补充) |
Approval |
Efficacy-Labeling Change With Clinical Data |
STANDARD
|
|
|
| 2016/11/14 |
SUPPL-9(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2016/01/29 |
SUPPL-7(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2015/12/21 |
SUPPL-8(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/03/30 |
SUPPL-6(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2015/02/23 |
SUPPL-4(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/09/23 |
SUPPL-3(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
| 2014/02/28 |
SUPPL-2(补充) |
Approval |
Labeling-Package Insert |
STANDARD
|
|
|
| 2013/10/03 |
SUPPL-1(补充) |
Approval |
Manufacturing (CMC) |
STANDARD
|
|
|
与本品相关的专利信息(来自FDA橙皮书Orange Book)
| 关联产品号 | 专利号 | 专利过期日 | 是否物质专利 | 是否产品专利 | 专利用途代码 | 撤销请求 | 提交日期 | 专利下载 | 备注 |
| 无 |
与本品治疗等效的药品
>>>活性成分:TOPOTECAN HYDROCHLORIDE; 剂型/给药途径:SOLUTION;INTRAVENOUS; 规格:EQ 4MG BASE/4ML (EQ 1MG BASE/ML); 治疗等效代码:AP<<<
| 申请号 | 产品号 | 申请类型 | 商品名 | 活性成分 | 剂型/给药途径 | 规格 | 市场状态 | RLD | RS | TE Code | 产品号批准日期 | 申请人 |
| 200582 |
001 |
NDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
EQ 4MG BASE/4ML (EQ 1MG BASE/ML) |
Prescription |
Yes |
Yes |
AP |
2011/02/02
|
HOSPIRA INC |
| 022453 |
001 |
NDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
EQ 4MG BASE/4ML (EQ 1MG BASE/ML) |
Discontinued |
No |
No |
AP |
2012/12/20
|
MEITHEAL |
| 204406 |
002 |
ANDA |
TOPOTECAN HYDROCHLORIDE |
TOPOTECAN HYDROCHLORIDE |
SOLUTION;INTRAVENOUS |
EQ 4MG BASE/4ML (EQ 1MG BASE/ML) |
Prescription |
No |
No |
AP |
2017/07/06
|
ACCORD HLTHCARE |